Related Experiment Video
Updated: Sep 20, 2026

Preparation of Cross-Linked Sodium Alginate Microspheres with Different Metal Ions Using the Microfluidic Electrospray Technology
Published on: June 7, 2024
Inflammation-responsive sodium alginate-based microalgal hydrogel with pH/ROS dual sensitivity for oral
Jia Ding1, Nan Wang1, Xiao-Kun Ouyang1
1School of Food and Pharmacy, Zhejiang Ocean University, Zhoushan, 316022, PR China.
Abstract:
Ulcerative colitis (UC) is associated with epithelial barrier disruption, oxidative stress, inflammation, and gut microbiota dysbiosis. Oral colon-localized delivery remains challenging because therapeutic cargos must resist gastric exposure, avoid premature release, be retained at inflamed colonic sites, and respond to pathological microenvironments. Herein, a pH/reactive oxygen species (ROS) dual-responsive calcium alginate microalgal hydrogel, denoted SP@GaTa@ALG (SGA), was developed for localized UC therapy. Gallium-tannic acid nanoparticles (GaTa NPs) were loaded onto Spirulina (SP) and encapsulated within a Ca2+-crosslinked alginate matrix. The calcium alginate network provided gastric protection and pH-dependent control over Ga3+ diffusion, while GaTa enabled ROS-responsive Ga3+ release and antioxidant activity. In vitro, SGA scavenged free radicals, reduced intracellular ROS accumulation, protected epithelial cells against H2O2-induced injury, preserved mitochondrial membrane potential, and promoted an anti-inflammatory-like macrophage phenotype. After oral administration, SGA showed prolonged gastrointestinal retention and enhanced colonic localization compared with non-encapsulated SP@GaTa (SG). In dextran sulfate sodium (DSS)-induced colitis mice, SGA alleviated body-weight loss, reduced disease activity, restored colon length, improved zonula occludens-1 (ZO-1) and Occludin expression, suppressed inflammatory mediators, and was associated with gut microbiota remodeling. These findings support SGA as a traceable, carbohydrate-polymer-based oral platform for inflammation-responsive UC intervention.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease II: Ulcerative Colitis
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Inflammatory Bowel Disease IV: Clinical Manifestations
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
